LAB Standard BioTools Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: LAB

Price (delayed)

$2.505

Market cap

$726.75M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.94

Enterprise value

$773.25M

Fluidigm focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, it develops, manufactures, and markets multi-omic solutions ...

Highlights
Standard BioTools's EPS has soared by 61% YoY and by 2.1% from the previous quarter
The company's net income has surged by 61% YoY
Standard BioTools's equity has shrunk by 82% YoY and by 12% QoQ
LAB's quick ratio has plunged by 71% YoY and by 56% from the previous quarter
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.fluidigm.com
Peers: RVTY QTRX PRPO

Key stats

What are the main financial stats of LAB
Market
Shares outstanding
290.12M
Market cap
$726.75M
Enterprise value
$773.25M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.86
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.27
Earnings
Revenue
$106.34M
EBIT
-$69.64M
EBITDA
-$65.66M
Free cash flow
-$46.12M
Per share
EPS
-$0.94
Free cash flow per share
-$0.58
Book value per share
-$1.86
Revenue per share
$1.34
TBVPS
$2.72
Balance sheet
Total assets
$323.07M
Total liabilities
$159.87M
Debt
$98.21M
Equity
-$148.05M
Working capital
$48.89M
Liquidity
Debt to equity
-0.66
Current ratio
1.45
Quick ratio
1.23
Net debt/EBITDA
-0.71
Margins
EBITDA margin
-61.7%
Gross margin
47.4%
Net margin
-70.2%
Operating margin
-72%
Efficiency
Return on assets
-21.5%
Return on equity
N/A
Return on invested capital
-39.5%
Return on capital employed
-32.6%
Return on sales
-65.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LAB stock price

How has the Standard BioTools stock price performed over time
Intraday
-0.99%
1 week
2.66%
1 month
-5.83%
1 year
67%
YTD
13.35%
QTD
-7.56%

Financial performance

How have Standard BioTools's revenue and profit performed over time
Revenue
$106.34M
Gross profit
$50.45M
Operating income
-$76.6M
Net income
-$74.66M
Gross margin
47.4%
Net margin
-70.2%
The net margin has surged by 64% year-on-year and by 2.5% since the previous quarter
The company's net income has surged by 61% YoY
LAB's operating margin is up by 39% year-on-year
Standard BioTools's gross profit has increased by 36% YoY and by 5% from the previous quarter

Growth

What is Standard BioTools's growth rate over time

Valuation

What is Standard BioTools stock price valuation
P/E
N/A
P/B
N/A
P/S
1.86
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.27
Standard BioTools's EPS has soared by 61% YoY and by 2.1% from the previous quarter
Standard BioTools's equity has shrunk by 82% YoY and by 12% QoQ
The P/S is 25% below the 5-year quarterly average of 2.5 but 11% above the last 4 quarters average of 1.7
Standard BioTools's revenue has increased by 9% YoY

Efficiency

How efficient is Standard BioTools business performance
Standard BioTools's ROS has soared by 66% YoY and by 2.1% from the previous quarter
The company's return on assets has surged by 57% YoY but it fell by 3.4% QoQ
The return on invested capital has increased by 45% year-on-year but it has declined by 13% since the previous quarter

Dividends

What is LAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LAB.

Financial health

How did Standard BioTools financials performed over time
LAB's total assets is 102% greater than its total liabilities
LAB's quick ratio has plunged by 71% YoY and by 56% from the previous quarter
The current ratio has plunged by 70% YoY and by 56% from the previous quarter
The debt is 166% greater than the equity
Standard BioTools's equity has shrunk by 82% YoY and by 12% QoQ
LAB's debt to equity is up by 48% year-on-year and by 13% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.